Discovery of the human induced pluripotent stem cell technology and development of physiologically relevant disease models using this technology has opened up new opportunities for testing toxicity and efficacy of new chemical entities (NCE) at early stages of drug discovery in human cell-based assays.
Ncardia is specialized in the development of various cell-based assays suitable for high throughput (up to 384 well plate format) compound screening using our proprietary hiPSC derived cardiomyocytes and neurons. To further increase the throughput and quality of our assays, we aim to automate all steps of cell culturing, compound addition and end-point readout in collaborations with Pivot Park Screening Center and Tecan liquid handling specialists using Fluent® automated liquid handling workstation. In this presentation we will show how we currently use the Fluent® workstation to develop optimal logistics for high-throughput compound screenings using hiPSC-derived cardiomyocytes.
Farbod Famili, Ncardia